Clinical trials in womens cancers

女性癌症的临床试验

• 批准号: 8938205
• 负责人: Christina Annunziata
• 金额: $ 23.66万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938205
• 关键词: Achievement; American Society of Clinical Oncology; Apoptosis; BAY 54-9085; Carboplatin; Clinic; Clinical Trials; Dasatinib; Data; Development; Drug Kinetics; Goals; Growth Factor; Hereditary Breast Carcinoma; Malignant Neoplasms; Malignant neoplasm of ovary; Manuscripts; Mutation; Outcome; Patients; Phase; Phase I Clinical Trials; Protein Family; Publishing; Research; Serous; Specimen; Testing; Therapeutic; Woman; Writing; angiogenesis; bevacizumab; cohort; inhibitor-of-apoptosis protein; meetings; mimetics; mutation carrier; triple-negative invasive breast carcinoma

Enter Project Summary Provide a written summary of the research accomplishments in FY2014 related to this project. The summary should clearly align with the goals and objectives of the project. Describe: major activities specific objectives significant results, including major findings, developments, or conclusions (both positive and negative) key outcomes or other achievements In 2014, I became the Acting Director of the Women's Malignancies Branch. Our Women's Cancer Clinic terminated one clinical trial (05C0022 - Bevacizumab and Sorafenib phase 1 with expansion cohort) after publishing the fifth and final manuscript using data and specimens collected on that trial. We also completed accrual to three clinical trials (12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer; 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer). The outcome and translational endpoints from these trials were presented at the 2014 ASCO Annual Meeting. We currently have three clinical trials open to accrual (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial).

输入项目摘要提供2014财年与该项目相关的研究成果的书面摘要。摘要应明确与项目的目标和目的相一致。描述：主要活动具体目标重要成果，包括主要发现、发展或结论（积极和消极）关键成果或其他成就2014年，我成为妇女肿瘤分支的代理主任。我们的女性癌症诊所在使用该试验收集的数据和标本发表了第五份也是最后一份手稿后终止了一项临床试验（05 C 0022-贝伐珠单抗和索拉非尼1期扩展队列）。我们还完成了三项临床试验的招募（12 C 0191-SMAC模拟物birinapant 2期治疗卵巢癌; 07 C 0058-贝伐珠单抗和索拉非尼2期治疗卵巢癌; 08 C 0092-卡铂和奥拉帕尼在三个患者队列中的应用：BRCA突变携带者、高级别浆液性卵巢癌、三阴性乳腺癌）。这些试验的结果和转化终点在2014年ASCO年会上公布。我们目前有三项临床试验开放供招募（11 C 0022-卡铂和奥拉帕尼在女性癌症中的药代动力学; 09 C 0019-贝伐珠单抗和达沙替尼1期试验; 1 - 2C 0081-奥拉帕尼和Cederinib在卵巢癌1-2期试验）。